Explore our insights

Pharma and healthcare deal activity in Q1 2026 reflects steady volumes alongside a more measured approach to capital deployment.

A global medical devices business operating in the orthopedic implants segment engaged Grant Thornton Bharat to support a strategic capital raise and debt restructuring.

Analyse M&A and investment activity in India’s financial services sector for Q1 2026, with insights on banking, fintech, deal trends and evolving market dynamics.

A stable start marked deal activity in the Indian real estate sector, with investors favouring measured capital deployment amid a relatively uncertain macro environment.

Explore M&A and investment activity in India’s automotive sector for Q1 2026, with insights on EV trends, deal activity and evolving market dynamics.

Explore M&A and investment activity in India’s consumer and retail sector for Q1 2026, with insights on deal trends, consumer behaviour and digital commerce growth.

Explore M&A and private equity deal activity in India for Q1 2026, with insights on sector trends, investment flows and market dynamics shaping the deal landscape.

India’s deal ecosystem continued to evolve in February 2026 with strong private equity activity, rising M&A transactions and sector-specific investment momentum shaping the country’s investment landscape.

The Monthly Dealtracker January 2026 review captures India’s deal environment with data on M&A, private equity, capital market values, sector highlights and macro trends shaping investment momentum and strategic transactions at the start of 2026.

Annual Dealtracker 2025 analyses India’s record deal activity, including M&A, PE/VC, and sector trends. The report highlights macro resilience, policy support, and deal momentum into 2026.

November 2025 marked a significant milestone for India’s deal environment, reflecting strong momentum across mergers and acquisitions and private equity transactions.

India’s deal activity in October 2025 reflected strong momentum across mergers, acquisitions, private equity, and public listings.

The Pharma and Healthcare Dealtracker Q3 2025 by Grant Thornton Bharat analyses India’s evolving life sciences ecosystem, highlighting a 28% surge in deal volumes and a 166% rise in values. The report explores M&A, private equity, and capital market activity shaping pharma, healthcare, and biotech growth.

The Q3 2025 edition of the Technology Dealtracker outlines this directional change, highlighting strategic movements across private equity and M&A, especially in mid-market and outbound segments.

The real estate sector demonstrated renewed momentum in Q3 2025, with notable activity across mergers and acquisitions, private equity, and capital markets. Institutional capital remained concentrated on income-generating commercial assets, supported by regulatory developments and increased access to domestic funding.

The Q3 2025 edition of Grant Thornton Bharat’s Financial Services Dealtracker analyses key deal trends across M&A, PE, IPOs, and QIPs. It explores investor sentiment, fintech-led innovation, and regulatory signals influencing capital flows in banking, NBFCs, insurance, and asset management.